.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,150,398

« Back to Dashboard

Claims for Patent: 6,150,398

Title: Methods for the treatment of cancer
Abstract:A pharmaceutical composition comprising an effective cancerous cell growth inhibiting amount of paclitaxel, or a paclitaxel derivative, and an effective cancerous cell growth inhibiting amount of an active agent which inhibits cancerous cell growth by exerting an effect on mammalian cell cycle during G.sub.1 or S-phase of the cell division cycle to inhibit said cancerous cell growth and methods of using same.
Inventor(s): Vande Woude; George F. (Berryville, VA), Schulz; Nicholas (Pittsburgh, PA), Zhou; Renping (Frederick, MD), Daar; Ira (Frederick, MD), Oskarsson; Marianne (Gaitherburg, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC)
Application Number:08/618,863
Patent Claims: 1. A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent, wherein said paclitaxel and DNA cross-linking anti-neoplastic agent act synergistically to inhibit cancerous cell growth in said human.

2. The method of claim 1, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth.

3. The method of claim 2, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during S phase to inhibit cancerous growth.

4. The method of claim 1, wherein said DNA cross-linking anti-neoplastic agent is cisplatin.

5. The method of claim 4, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth.

6. The method of claim 5, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during S phase to inhibit cancerous growth.

7. A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent, wherein said paclitaxel exerts an effect on a human cell division cycle during M phase to inhibit cancerous growth, said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth, and said paclitaxel and DNA cross-linking anti-neoplastic agent act synergistically to inhibit cancerous cell growth in said human.

8. The method of claim 7, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during S phase to inhibit cancerous growth.

9. The method of claim 7, wherein said DNA cross-linking anti-neoplastic agent is cisplatin.

10. The method of claim 9, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during S phase to inhibit cancerous growth.

11. A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent,

wherein said paclitaxel and DNA cross-linking anti-neoplastic agent are administered within eight hours of each other and

act synergistically to inhibit cancerous cell growth in said human.

12. The method of claim 11, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth.

13. The method of claim 11, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during S phase to inhibit cancerous growth.

14. The method of claim 11, wherein said DNA cross-linking anti-neoplastic agent is cisplatin.

15. The method of claim 14, wherein said DNA cross-linking anti-neoplastic agent is administered so as to exert an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth.

16. The method of claim 15, wherein said DNA cross-linking anti-neoplastic agent is administered so as to exert an effect on a human cell division cycle during S phase to inhibit cancerous growth.

17. A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent,

wherein said placlitaxel exerts an effect on a human cell division cycle during M phase to inhibit cancerous growth,

said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth,

said paclitaxel and DNA cross-linking anti-neoplastic agent are administered within eight hours of each other, and

said paclitaxel and DNA cross-linking anti-neoplastic agent act synergistically to inhibit cancerous cell growth in said human.

18. The method of claim 17, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during S phase to inhibit cancerous growth.

19. The method of claim 17, wherein said DNA cross-linking anti-neoplastic agent is cisplatin.

20. The method of claim 19, wherein said wherein said DNA cross-linking anti-neoplastic agent is administered so as to exert an effect on a human cell division cycle during S phase to inhibit cancerous growth.

21. A method of treating cancer by administering to a human paclitaxel and DNA cross-linking anti-neoplastic agent,

wherein said paclitaxel and DNA cross-linking anti-neoplastic agent are administered within one hour of each other and

act synergistically to inhibit cancerous cell growth in said human.

22. The method of claim 21, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth.

23. The method of claim 22, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during S phase to inhibit cancerous growth.

24. The method of claim 17, wherein said DNA cross-linking anti-neoplastic agent is cisplatin.

25. The method of claim 21, wherein said DNA cross-linking anit-neoplastic agent is administered so as to exert an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth.

26. The method of claim 25, wherein said DNA cross-linking anti-neoplastic agent is administered so as to exert an effect on a human cell division cycle during S phase to inhibit cancerous growth.

27. A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent,

wherein said placlitaxel exerts an effect on a human cell division cycle during M phase to inhibit cancerous growth, said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth,

said paclitaxel and DNA cross-linking anti-neoplastic agent are administered within one hour of each other, and

said paclitaxel and DNA cross-linking anti-neoplastic agent act synergistically to inhibit cancerous cell growth in said human.

28. The method of claim 27, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during S phase to inhibit cancerous growth.

29. The method of claim 27, wherein said DNA cross-linking anti-neoplastic agent is cisplatin.

30. The method of claim 29, wherein said DNA cross-linking anti-neoplastic agent is administered so as to exert an effect on a human cell division cycle during S phase to inhibit cancerous growth.

31. A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent,

wherein said paclitaxel and DNA cross-linking anti-neoplastic agent are administered to said human in such temporal proximity to each other so as to simultaneously achieve levels of said paclitaxel and DNA cross-linking anti-neoplastic agent in said human sufficient to act synergistically to inhibit cancerous cell growth in said human.

32. The method of claim 31, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth.

33. The method of claim 32, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during S phase to inhibit cancerous growth.

34. The method of claim 31, wherein said DNA cross-linking anti-neoplastic agent is cisplatin.

35. The method of claim 34, wherein said DNA cross-linking anti-neoplastic agent is administered so as to exert an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth.

36. The method of claim 35, wherein said DNA cross-linking anti-neoplastic agent is administered so as to exert an effect on a human cell division cycle during S phase to inhibit cancerous growth.

37. A method of treating cancer by administering to a human paclitaxel and a DNA cross-linking anti-neoplastic agent in such temporal proximity to each other so as to simultaneously achieve levels of said paclitaxel and DNA cross-linking anti-neoplastic agent in said human sufficient to act synergistically to inhibit cancerous cell growth in said human,

wherein said paclitaxel exerts an effect on a human cell division cycle during M phase to inhibit cancerous growth, and

said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during G.sub.1 or S phase to inhibit cancerous growth.

38. The method of claim 37, wherein said DNA cross-linking anti-neoplastic agent exerts an effect on a human cell division cycle during S phase to inhibit cancerous growth.

39. The method of claim 37, wherein said DNA cross-linking anti-neoplastic agent is cisplatin.

40. The method of claim 39, wherein said DNA cross-linking anti-neoplastic agent is administered so as to exert an effect on a human cell division cycle during S phase to inhibit cancerous growth.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc